TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis
Brief Summary: The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with psychosis.

The main objective of the TEA trial is to compare the efficacy and adverse reactions of two antipsychotics (quetiapine versus aripiprazole) in children and adolescents between 12-17 years of age with psychotic symptoms on psychopathology, cognitive deficits, and daily functioning. Furthermore, the trial will focus on adverse reaction profiles of the two antipsychotics as well as early predictors of later sustained clinical effects of these antipsychotics.


Options:
A: Arm Label: Aripirazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Quetiapine prolong; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripirazole | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine prolong
B: Arm Label: Methylphenidate transdermal system; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate transdermal system
C: Arm Label: 001; Type: N/A; Interventions: Other: Observational treatment compliance survey | Intervention Type: OTHER; Name: Observational treatment compliance survey; Assigned to Arm(s): 001
D: Arm Label: 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 15 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsules; Assigned to Arm(s): 10 mg, 15 mg, 20 mg, 40 mg, Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Vitamin D on Balance in Persons With PD
Brief Summary: A trial to measure the effects of vitamin D (versus a placebo) on balance, gait, falls, strength, and cognition in persons with Parkinson's disease.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: interactive video game-based exercise, Other: no intervention | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Other: interactive video game-based exercise, Other: no intervention | Intervention Type: OTHER; Name: interactive video game-based exercise; Assigned to Arm(s): Group A, Group B | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): Group A, Group B
B: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy aimed to improve Physical Activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy aimed to move safely | Intervention Type: OTHER; Name: Physical therapy aimed to move safely; Assigned to Arm(s): B | Intervention Type: OTHER; Name: Physical Therapy aimed to improve Physical Activity; Assigned to Arm(s): A
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3, Dietary Supplement: calcium | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium, Other: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Arm 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Patient Understanding of Preeclampsia
Brief Summary: Participants counseled with the preeclampsia educational tool will have a better understanding of preeclampsia than those not counseled using the tool.


Options:
A: Arm Label: Group Education; Type: EXPERIMENTAL; Interventions: Other: Group Education | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Group Education; Assigned to Arm(s): Group Education
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ACOG education pamphlet on preeclampsia | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Preeclampsia education tool | Intervention Type: BEHAVIORAL; Name: ACOG education pamphlet on preeclampsia; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Preeclampsia education tool; Assigned to Arm(s): 3
C: Intervention Type: BEHAVIORAL; Name: Family Spirit curriculum; Assigned to Arm(s): N/A
D: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis
Brief Summary: GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect information on the safety of GMI-1070, how much of the drug is in the blood and urine, and if there are any other effects when used in patients who are in the hospital for a sickle cell pain crisis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen, Drug: Diamorphine or Morphine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Diamorphine or Morphine | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Diamorphine or Morphine; Assigned to Arm(s): 1, 2
C: Arm Label: High Demand / Low Infusion; Type: OTHER; Interventions: Other: High Demand / Low Infusion | Arm Label: Low Demand / High Infusion; Type: OTHER; Interventions: Other: PCA Dosing Plan | Intervention Type: OTHER; Name: High Demand / Low Infusion; Assigned to Arm(s): High Demand / Low Infusion | Intervention Type: OTHER; Name: PCA Dosing Plan; Assigned to Arm(s): Low Demand / High Infusion
D: Arm Label: GMI-1070; Type: EXPERIMENTAL; Interventions: Drug: GMI-1070 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GMI-1070; Assigned to Arm(s): GMI-1070 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Brief Summary: This randomized, blinded, parallel arm study evaluated the efficacy and safety of tocilizumab (RoActemra/Actemra) versus adalimumab as monotherapy in patients with rheumatoid arthritis who are intolerant of methotrexate or where continued treatment with methotrexate was considered inappropriate. Patients were randomized to receive either tocilizumab 8 mg/kg intravenously (iv) every 4 weeks plus placebo subcutaneously (sc) every 2 weeks, or adalimumab 40 mg sc every 2 weeks plus placebo iv every 4 weeks. Treatment was anticipated to last 24 weeks. With regard to the blind, the study nurse was unblinded due to the nature of the treatment administration, but the investigator and the patient remained blinded.


Options:
A: Arm Label: Tocilizumab 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Placebo to adalimumab | Arm Label: Adalimumab 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab, Drug: Placebo to tocilizumab | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to tocilizumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to adalimumab; Assigned to Arm(s): Tocilizumab 8 mg/kg
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
C: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Brief Summary: This randomized, blinded, parallel arm study evaluated the efficacy and safety of tocilizumab (RoActemra/Actemra) versus adalimumab as monotherapy in patients with rheumatoid arthritis who are intolerant of methotrexate or where continued treatment with methotrexate was considered inappropriate. Patients were randomized to receive either tocilizumab 8 mg/kg intravenously (iv) every 4 weeks plus placebo subcutaneously (sc) every 2 weeks, or adalimumab 40 mg sc every 2 weeks plus placebo iv every 4 weeks. Treatment was anticipated to last 24 weeks. With regard to the blind, the study nurse was unblinded due to the nature of the treatment administration, but the investigator and the patient remained blinded.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: Tocilizumab 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Placebo to adalimumab | Arm Label: Adalimumab 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab, Drug: Placebo to tocilizumab | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to tocilizumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to adalimumab; Assigned to Arm(s): Tocilizumab 8 mg/kg
D: Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Pilot Study of Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome(ARDS): Individualized According to the Best Compliance or Fixed According to Fraction of Inspired Oxygen (FiO2) Applied
Brief Summary: Randomized controlled pilot trial in 70 patients with Acute Respiratory Distress Syndrome (ARDS) ventilated with low tidal volumes and limitation on airway pressure at 35 centimeters of water (cmH2O), to compare two different methods of selecting the level of Positive End-Expiratory Pressure (PEEP) to be applied: according to fraction of inspired oxygen (FiO2) needed or individualized according to the best compliance. Primary objective was evolution of arterial oxygenation during the 28 days. Secondary objectives were to measure its effects on hemodynamic parameters, 28-day mortality, number of ventilator-free days at day 28, Intensive Care Unit (ICU) and hospital stay, number of multiple-organ dysfunction-free days and a multivariate analysis of 28 day-mortality.


Options:
A: Arm Label: Focal ARDS; Type: EXPERIMENTAL; Interventions: Procedure: Mechanical ventilation | Arm Label: non focal ARDS; Type: OTHER; Interventions: Procedure: Mechanical ventilation | Intervention Type: PROCEDURE; Name: Mechanical ventilation; Assigned to Arm(s): Focal ARDS, non focal ARDS
B: Arm Label: One Group; Type: N/A; Interventions: N/A
C: Arm Label: Compliance-guided PEEP group; Type: OTHER; Interventions: Other: Positive End-expiratory Pressure (PEEP) | Arm Label: FiO2-driven-PEEP group; Type: OTHER; Interventions: Other: Positive End-expiratory Pressure (PEEP) | Intervention Type: OTHER; Name: Positive End-expiratory Pressure (PEEP); Assigned to Arm(s): Compliance-guided PEEP group, FiO2-driven-PEEP group
D: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Brief Summary: The objective of the study is to determine if a weekly dose of 17 hydroxyprogesterone caproate (17P, Makena®) given to women with preterm rupture of the membranes will:

1. increase the probability of continuing the pregnancy until a favorable gestational age.
2. increase the interval between randomization and delivery.
3. decrease neonatal morbidity.


Options:
A: Arm Label: 17-alpha hydroxyprogesterone caproate, Makena®; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17-alpha-hydroxy-progesterone caproate, Makena® | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Castor Oil (Placebo) | Intervention Type: DRUG; Name: 17-alpha-hydroxy-progesterone caproate, Makena®; Assigned to Arm(s): 17-alpha hydroxyprogesterone caproate, Makena® | Intervention Type: DRUG; Name: Castor Oil (Placebo); Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 17 alpha-hydroxyprogesterone caproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 alpha-hydroxyprogesterone caproate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Oil | Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate; Assigned to Arm(s): 17 alpha-hydroxyprogesterone caproate | Intervention Type: OTHER; Name: Placebo Oil; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator All Administered Twice Daily by Inhalation in Patients With Stable Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug, formoterol 12 µg, and placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).after 7 days on treatment. Every treatment period is 7-days long and there is a 5 to 7-days wash-out period in between them. The trial starts with a run in phase of 11 to 17-days duration and it ends up with a follow up contact 14-days after last treatment dose.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2
B: Arm Label: Aclidinium bromide 100 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 100 μg bid | Arm Label: Aclidininum bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidininum bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Formoterol 12 μg bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol 12 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 100 μg bid; Assigned to Arm(s): Aclidinium bromide 100 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidininum bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidininum bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol 12 μg bid; Assigned to Arm(s): Formoterol 12 μg bid
C: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Study to Evaluate the Efficacy of 1,25(OH)2D3 (Calcitriol) Versus Placebo in Recent Onset Type 1 Diabetes(IMDIAB XIII)
Brief Summary: Reduction in vitamin D levels has been reported in subjects with recent onset type 1 diabetes. Several studies suggest that vitamin D supplementation in early childhood decreases the risk of developing type 1 diabetes, therefore vitamin D deficiency might play a role in the disease pathogenesis. We investigated whether the supplementation of the active form of vitamin D (calcitriol) in subjects with recent-onset type 1 diabetes can protect residual beta cell function evaluated by C peptide and improve glycaemic control as evaluated by HbA1c and insulin requirement.

Thirty-four subjects (age range 11-35 years, median 18 years) with recent-onset type 1 diabetes (\<12 weeks duration) and high basal C-peptide \>0.25 nmol/l were randomized in a double-blind trial to calcitriol (the active form of vitamin D, 1.25-dihydroxyvitamin D3 \[1,25-(OH)2D3\] ) at the dose of 0.25 ug/day or placebo, and followed up for 2 years.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cure | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Calcitriol; Type: EXPERIMENTAL; Interventions: Drug: Calcitriol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Calcitriol | Intervention Type: DRUG; Name: Calcitriol; Assigned to Arm(s): Calcitriol, placebo

Answer: D